Compare EXPO & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXPO | TNGX |
|---|---|---|
| Founded | 1967 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 2.8B |
| IPO Year | 1996 | 2020 |
| Metric | EXPO | TNGX |
|---|---|---|
| Price | $66.56 | $21.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $88.00 | $20.00 |
| AVG Volume (30 Days) | 425.4K | ★ 3.7M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.86% | N/A |
| EPS Growth | N/A | ★ 26.89 |
| EPS | ★ 2.07 | N/A |
| Revenue | ★ $582,014,000.00 | $62,384,000.00 |
| Revenue This Year | $12.75 | N/A |
| Revenue Next Year | $8.50 | N/A |
| P/E Ratio | $32.11 | ★ N/A |
| Revenue Growth | 4.21 | ★ 48.29 |
| 52 Week Low | $63.25 | $1.04 |
| 52 Week High | $83.92 | $22.20 |
| Indicator | EXPO | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 45.42 | 74.32 |
| Support Level | $64.55 | $5.98 |
| Resistance Level | $73.91 | $21.82 |
| Average True Range (ATR) | 2.17 | 1.24 |
| MACD | 0.11 | 0.08 |
| Stochastic Oscillator | 54.67 | 90.10 |
Exponent Inc is a science and engineering consulting firm that provides solutions to complex problems. The company's consultant team is composed of scientists, physicians, engineers, as well as business and regulatory consultants. The company currently operates through two segments. The engineering and other scientific segments, which account for the majority of revenue, provide servicing encompassing biomechanics, biomedical engineering, buildings and structures, civil engineering, construction consulting, etc. The environmental and health segment covers chemical regulation and food safety, ecological and biological sciences, environmental and earth sciences and others. The company generates almost all of its revenues from America.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.